TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells-Reference-Cited by-同舟云学术

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Published:2018-02 Issue:7693 Volume:554 Page:544-548
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Mariathasan Sanjeev,Turley Shannon J.,Nickles Dorothee,Castiglioni Alessandra,Yuen Kobe,Wang Yulei,Kadel III Edward E.,Koeppen Hartmut,Astarita Jillian L.,Cubas Rafael,Jhunjhunwala Suchit,Banchereau Romain,Yang Yagai,Guan Yinghui,Chalouni Cecile,Ziai James,Şenbabaoğlu Yasin,Santoro Stephen,Sheinson Daniel,Hung Jeffrey,Giltnane Jennifer M.,Pierce Andrew A.,Mesh Kathryn,Lianoglou Steve,Riegler Johannes,Carano Richard A. D.,Eriksson Pontus,Höglund Mattias,Somarriba Loan,Halligan Daniel L.,van der Heijden Michiel S.,Loriot Yohann,Rosenberg Jonathan E.,Fong Lawrence,Mellman Ira,Chen Daniel S.,Green Marjorie,Derleth Christina,Fine Gregg D.,Hegde Priti S.,Bourgon Richard,Powles Thomas

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/nature25501.pdf

Reference34 articles.

1. Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563–567 (2014)

2. Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558–562 (2014)

3. Bellmunt, J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 376, 1015–1026 (2017)

4. Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909–1920 (2016)

5. Balar, A. V. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389, 67–76 (2017)

Cited by 3580 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High dimensional discriminant rules with shrinkage estimators of the covariance matrix and mean vector;Journal of Statistical Planning and Inference;2025-01

2. Molecular classification of geriatric breast cancer displays distinct senescent subgroups of prognostic significance;Molecular Therapy - Nucleic Acids;2024-12

3. A multi-task deep learning model based on comprehensive feature integration and self-attention mechanism for predicting response to anti-PD1/PD-L1;International Immunopharmacology;2024-12

4. UBAP2 contributes to radioresistance by enhancing homologous recombination through SLC27A5 ubiquitination in hepatocellular carcinoma;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-12

5. Bulk and single-cell RNA sequencing analyses coupled with multiple machine learning to develop a glycosyltransferase associated signature in colorectal cancer;Translational Oncology;2024-11